Quince Therapeutics to Participate at Upcoming Investor Conferences
Quince Therapeutics, Inc. (QNCX)
Company Research
Source: Business Wire
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced that management will present at three upcoming investor conferences:2024 Maxim Healthcare Virtual Summit – Quince’s Chief Executive Officer and Chief Medical Officer Dirk Thye, M.D., will participate in a fireside chat on Thursday, October 17, 2024 beginning at 3:00 p.m. Eastern Time. Qualified investors can register here to access the live event.LD Micro Main Event XVII – Quince’s Chief Operating Officer and Chief Business Officer Brendan Hannah will present a company overview on Tuesday, October 29, 2024 beginning at 6:30 p.m. Eastern Time. Please register here to access the live presentation.The ThinkEquity Conference 2024 – Quince’s President Charles Ryan, J.D., Ph.D., will present a company overview on October 30, 2024 beginning at 3:00 p.m. Eas
Show less
Read more
Impact Snapshot
Event Time:
QNCX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
QNCX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
QNCX alerts
High impacting Quince Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
QNCX
News
- Quince Therapeutics files for $200M mixed securities shelf [Seeking Alpha]Seeking Alpha
- Quince Therapeutics, Inc. (NASDAQ: QNCX) is now covered by analysts at Brookline Capital Management. They set a "buy" rating and a $9.00 price target on the stock.MarketBeat
- Quince Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial ResultsBusiness Wire
- Quince Therapeutics Presents Data from Prior Phase 3 ATTeST Clinical Trial at 2024 International Congress for Ataxia ResearchBusiness Wire
- Quince Therapeutics Presents Safety Data from Prior Phase 3 ATTeST Clinical Trial at 53rd Child Neurology Society Annual MeetingBusiness Wire
QNCX
Sec Filings
- 12/18/24 - Form S-3
- 11/14/24 - Form SC
- 11/14/24 - Form 8-K
- QNCX's page on the SEC website